Latest News

Stay updated with the latest healthcare breakthroughs, including phase 3 data, new clinical findings, and regulatory updates.

Butler explains why the urine albumin-to-creatinine ratio belongs in routine heart failure risk assessment and where the open questions remain.

MOMENTUM data suggest hypercortisolism prevalence reached 43.6% among individuals with resistant hypertension and an eGFR below 45 mL/min/1.73 m².

Pediatric studies show dupilumab boosts height gains, eases caregiver-reported symptoms by week 2, and maintains strong skin clearance for 3 years.

Phase 3 FIND-CKD data show finerenone slows kidney function decline in non-diabetic chronic kidney disease, extending the agent's role beyond diabetic CKD.

A Family Heart Database analysis found only 1.1% of US adults have undergone lipoprotein(a) testing.

This Q&A interview with Mona Shahriari, MD, highlights key atopic dermatitis tips, new developments, and themes from her session at RAD 2026.

A secret shopper study of 49 websites selling GLP-1 receptor agonists found more than 90% issued a prescription, often without bloodwork, photo verification, or clinician interaction.

Multiple trials at RAD 2026 highlight the efficacy and safety of delgocitinib in chronic hand eczema.

Roflumilast cream data from RAD 2026 shed further light on the efficacy and safety across the age spectrum.

HCPLive convened an in-depth roundtable discussion on advancing biologic therapy for asthma and COPD in a complex real-world prescribing environment.

ARCADIA LTE data show nemolizumab maintains EASI-75 in over 90% of responders through 2 years and phase 2 pediatric data shed further light at RAD 2026.

A propensity-matched study shows dupilumab reduces gastrointestinal and endocrine IMID risk by 43-46% but raises psoriasis risk by 24%.

Tatyana Kushner, MD, joins hosts Brown and Reau to discuss HDV testing gaps, bulevirtide approval, and the emerging delta hepatitis pipeline.

Data from the ongoing open-label extensions of PATHFNDR-1 and PATHFNDR-2, presented at ENDO 2026, highlight the drug’s efficacy in reducing IGF-1.

This episode covers recent approvals and updated indications allowing more treatment options for children with diabetes.

RAD 2026 analyses reveal the impact of CHE on patients' lives, including its financial effects and influence on treatment decision-making.

Real-world data from the international TRACE study show 12 months of tralokinumab improved skin and quality-of-life outcomes.

An expert clinical forum explores recent updates in the field and incorporating sotatercept treatment.

Explore APAPP’s Las Vegas meeting with hands-on POCUS and airway labs, COPD and ILD bootcamps, AI updates, and new therapy insights.

This discussion centers on patient empowerment, shared decision-making, and advancing equitable dermatologic care for those with skin of color.

Baseline characteristics, including sex and comorbidities, were associated with semaglutide weight loss outcomes in >36,000 adults.

Fezolinetant's CNS safety Profile Reassures Across More Than 3,000 Women in Pooled Phase 3 Analysis at ENDO 2026